XLV rallied 101bps last week in very low volume and is now testing heavy resistance between $136 and $137. Should a
pullback occur, look for support at the rising 21-DMA ($133.77). Its RS line has started to rise, but has yet to make a
higher high, warranting an equal-weight sector positioning.
Author: Raj Gupta
Market View
The U.S. market remains in a Confirmed Uptrend. S&P 500 advanced for a ninth consecutive week, gaining 0.3%, while the Nasdaq paused after eight weeks of gains, trading just slightly lower. Immediate support for the indices is seen along their respective 10-DMA (4,754/14,975), followed by the 21-DMA (4,686/14,714). The S&P 500 has resistance near January 2022 high of ~4,800, while the Nasdaq has resistance near the 15,320 level. Indices each picked up a fourth distribution day on Friday. The distribution day count for both indices is four, with one set to expire on the S&P 500 next week.
O’Neil Health Care Weekly
XLV gained 64bps last week after rallying from 21-DMA support ($132.68). The next range of resistance is $136 to $137. Despite
absolute action remaining intact, its RS line is still in a downtrend warranting an under- to equal-weight sector positioning.
Market View
The U.S. market remains in a Confirmed Uptrend. The S&P 500 and the Nasdaq rose for the eighth consecutive week despite
briefly pulling back and testing support at the 10-DMA (4,707/14,787). The S&P 500 is approaching resistance near ~4,800 (+1%) or
all-time highs, while the Nasdaq is testing resistance near the 15,320 (+2%) level. The distribution day count for both indices remains
at three.
O’Neil Health Care Weekly
XLV gained 1.58% last week, faced resistance at $136 level and pulled back. Support is at 21-DMA ($131.51). RS line is consolidating
warranting an under- to equal-weight sector positioning.
Market View
The U.S. market remains in a Confirmed Uptrend. The S&P 500 rose 2.5% for a seventh week of gains, breaking through July 2023 resistance and clearly into 52-week highs. It is a bit extended short-term as it nears the next potential resistance level from its January 2022 peak (4,749). The Nasdaq also rose for a seventh week (+2.8%), clearing above both July 2023 and March 2022 peaks. Next resistance is its January 2022 peak (15,319). Immediate support for S&P 500 and Nasdaq is their respective 10-DMA (4,628/14,457), followed by the 21-DMA (4,582/14,312). The distribution day count is down to two each, from three to start the week.
O’Neil Health Care Weekly
XLV gained 18bps last week, trading relatively flat for the second straight week and holding above all key moving averages including
support at its 200-DMA ($130.75). Support below this level remains the rising 21-DMA ($130.28). The next level of resistance is ~$135.
Its RS line has remained sideways for the trailing three-weeks, but has yet to make a significant move higher, which still warrants an
equal-to underweight sector positioning.
Market View
The U.S. market remains in a Confirmed Uptrend. The S&P 500 is testing July highs (4,607) while the Nasdaq is consolidating below its July resistance level (14,447). The first level of support is at the 10-DMA (4,566/14,251), followed by the rising 21-DMA (4,519/14,093). Both indices added one distribution day this week, increasing the count to three on each index.
IPO Rewind
Attached is our monthly IPO Rewind report. This report identifies a select group of IPOs or spin-offs that have priced in the last two years, giving them time to digest any initial volatility. Our selected ideas display positive fundamental trends with strong top- and bottom-line consensus estimates, and IPO Rewind provides an efficient way to review these ideas that we believe warrant attention.
O’Neil Health Care Weekly
XLV gained 53bps last week, closing above all key moving averages including support at its 200-DMA ($130.72). Support below this
level remains the rising 21-DMA ($129.24). The next level of resistance is ~$135. Its RS line has remained sideways for the trailing
three-weeks, but has yet to make a significant move higher, which still warrants an equal-to underweight sector positioning.